Regarding EGFR gene amplification, the phase II trial testing ABT-414 (also known as depatuxizumab mafodotin), an anti-EGFR monoclonal antibody conjugated to a potent antimitotic agent (monomethyl auristatin F), in patients with a recurring GBM with EGFR amplification, observed a response in 39% of patients [26]. This evidence concerns the gene EGFR and glioblastoma.